Aehr Test Systems vs InMode Ltd — how do they compare? Aehr Test Systems trades at $129.23 (market cap $3.82B), while InMode Ltd trades at $15.25 (market cap $872.08M). The key difference: Aehr Test Systems is far larger — about 4.4× InMode Ltd's market cap, and Aehr Test Systems is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| AEHR | INMD | |
|---|---|---|
Market Cap | $3.82B | $872.08M |
Sector | Technology | Technology |
52-Week High | $117.18 | $16.62 |
52-Week Low | $17.38 | $12.76 |
Enterprise Value | $3.72B | $375.42M |
Signals from Pluang's Aura AI — not financial advice
Aehr Test Systems (AEHR) trades at $129.23, up 21.69% in the last 24 hours, reflecting strong momentum. The stock is technically bullish, trading near resistance at $129, with a high RSI suggesting potential overbought conditions. Fundamentally, the company reported a net loss of $3.91 million for 2025, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a $22 million follow-on order for AI processor wafer-level burn-in systems, signaling robust demand in high-growth sectors.
The outlook is supported by record bookings and a strategic pivot to AI infrastructure, though high valuation multiples and insider selling pose risks. Revenue growth guidance of 160-200% for FY27 offers significant upside potential, but investor caution is warranted due to customer concentration and current unprofitability.
INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.
The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.
Trailing returns across standard periods
Latest headlines on both assets
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →